Human IFN-alpha 2/IFNA2 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB93452
Key Product Details
Species Reactivity
Human
Applications
Neutralization
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # 967305
Product Specifications
Immunogen
HEK293 human embryonic kidney cell line transfected with human IFN‑ alpha2/IFNA2
Met1-Glu188
Accession # P01563
Met1-Glu188
Accession # P01563
Specificity
Detects human IFN‑ alpha2/IFNA2 in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human IFN-alpha 2/IFNA2 Antibody
IFN‑ alpha2/IFNA2 Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN‑ alpha2/IFNA2 Antibody.
Recombinant Human IFN-alpha 2/IFNA2 reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IFN-alpha 2/IFNA2 (0.25 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IFN-alpha 2/IFNA2 Monoclonal Antibody (Catalog # MAB93452). The ND50 is typically 0.6-3.6 ng/mL.Applications for Human IFN-alpha 2/IFNA2 Antibody
Application
Recommended Usage
Neutralization
Measured by its ability to neutralize IFN‑ alpha2/IFNA2 inhibition of EMCV-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line. The Neutralization Dose (ND50) is typically 0.6-3.6 ng/mL in the presence of 0.25 ng/mL Recombinant Human IFN‑ alpha2/IFNA2.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IFN-alpha 2/IFNA2
IFNA2 is a ligand for a cell surface receptor with two subunits, IFN-alpha R2 (ligand binding) and IFN-alpha R1 (ligand binding and signal transduction). IFNA2 has both antiviral and immunomodulatory activities on target cells. Intranasal administration has been shown to reduce viral load in subjects with the common cold. While IFNA2 is a prognostic factor for hepatocellular carcinoma, Interferon alpha 2b, has been used to treat melanoma, renal cell carcinoma, chronic myelogenous leukemia and hepatitis C.
References
- Chen, Zy et al. (2014) Br. J. Cancer 110:733.
- Burchert, A. et al. (2015) Leukemia 29:1331.
- Perrakis, A. et al. (2011) Transplant Proc. 43:3824.
- Akaza, H. et al. (2011) Jpn. J. Clin. Oncol. 41:1023.
Long Name
Interferon alpha 2
Alternate Names
Ifa2, IFNA2, IFNA2a, IFNA2b, IFNA2c, IFNAA, IFNalpha 2
Gene Symbol
IFNA2
UniProt
Additional IFN-alpha 2/IFNA2 Products
Product Documents for Human IFN-alpha 2/IFNA2 Antibody
Product Specific Notices for Human IFN-alpha 2/IFNA2 Antibody
For research use only
Loading...
Loading...
Loading...